# A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

> **NCT05370755** · PHASE1 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 22 (estimated)

## Conditions studied

- Patients With Advanced Solid Tumors

## Interventions

- **DRUG:** ICP-189

## Key facts

- **NCT ID:** NCT05370755
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-31
- **Primary completion:** 2024-05-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05370755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05370755, "A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05370755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*